Progestin vs Progesterone for HRT: What the Evidence Actually Shows

The side-by-side comparison

The HRT Indexis the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified for this page

On a page about cancer risk, sourcing matters more than our opinion.

Is progestin the same as progesterone for HRT?

No. “Progestogen” is the umbrella word for the whole family. “Progesterone” is one specific molecule — the one your ovaries produced. “Progestin” means any synthetic member of the family: medroxyprogesterone acetate, norethindrone acetate, levonorgestrel, drospirenone. All of them switch on the progesterone receptor and thin the uterine lining. They behave differently everywhere else in the body.

Progestogenis the category. Think of it like “citrus.”

Progesterone is the single hormone your ovaries made every month after ovulation. The prescription version is called micronized progesterone.“Micronized” means the particles are ground extremely fine — that’s what makes it absorbable enough to work as a capsule you swallow.

Progestin means synthetic. Chemists built these molecules in labs starting in the 1950s, mostly for birth control. They latch onto the same receptor as progesterone. They are not the same shape.

Why even the experts blur the words

The FDA’s own consumer page on menopause says: “Estrogen with or without progestogen (also known as progestin).” It treats the umbrella term and the synthetic subgroup as synonyms.

And the patient leaflet folded inside a box of Prometrium— which contains progesterone, not a progestin — uses the word progestinwhen it explains to women what’s reducing their uterine cancer risk.

The FDA-approved progesterone product calls itself a progestin in its own patient handout. If the labels can’t keep these words straight, the fact that your search results are a mess isn’t a personal failing. It’s a naming problem the whole field inherited.

The family tree, plainly

That last grouping is why progestins don’t all behave the same. Lumping them into one bucket called “synthetic” and comparing that bucket to progesterone is scientifically sloppy — and it’s exactly what most of the studies you’ll read had to do, because the numbers were too small to separate them.

Do I need progesterone or a progestin with estrogen?

If you have a uterus and take systemic estrogen — a patch, pill, gel, or spray that reaches your whole body — estrogen alone thickens the uterine lining and raises endometrial cancer risk over time. A progestogen opposes that. It is not optional. When the FDA approved its first batch of hormone therapy labeling changes in February 2026, it deliberately kept the endometrial cancer warning on estrogen-alone products for women with a uterus.

Your endometriumis the lining of your uterus. Estrogen tells it to grow. Progesterone (or a progestin) tells it to stop and shed. Without that second signal, the lining keeps building — a condition called endometrial hyperplasia, which can progress to cancer.

The number that shows why this isn’t negotiable

The Prometrium label contains a three-year randomized trial. Women took conjugated estrogens (Premarin) with or without progesterone. Here’s what the biopsies found:

Sixty-four percent. That’s not a theoretical risk. That’s what happens to the lining of most women’s uteruses when estrogen goes in unopposed for three years.

If you’ve had a hysterectomy

No uterus, no endometrium, no endometrial cancer risk from estrogen. The Menopause Society is clear that estrogen-alone therapy is appropriate for women without a uterus. Bijuva’s label says it plainly: if you don’t have a uterus, you don’t need a progestogen, and you shouldn’t use one. Some women without a uterus are still prescribed progesterone for sleep or mood — that’s off-label. Read our HRT safety guide instead →

If you only use vaginal estrogen

Low-dose vaginal estrogen— a cream, tablet, insert, or ring used for vaginal dryness — acts mostly where you put it. The Menopause Society states that a progestogen is generally not indicated with recommended low-dose vaginal estrogen. Two conditions: this applies to recommended low doses, and any bleeding after menopause needs evaluation whatever you’re using. Learn more about vaginal estrogen →

The exception almost nobody knows about

There is one FDA-approved way to take systemic estrogen with a uterus and no progestogen at all. Duavee combines conjugated estrogens with bazedoxifene, a drug that blocks estrogen’s effect on the uterine lining specifically. It’s approved for hot flashes and osteoporosis prevention in women with a uterus. No progesterone. No progestin.

It isn’t right for everyone, and it isn’t widely prescribed — ask whether it’s available. But if progestogens make you feel terrible and you didn’t know this existed, that’s worth a sentence at your next appointment.

The number you heard — and what it doesn’t tell you

You probably arrived with one statistic: in the French E3N study, estrogen plus progesterone carried a breast cancer relative risk of 1.00, while estrogen plus other progestogens carried 1.69. That number is real, correctly cited, and drawn from 80,377 women. It is also observational, has never been confirmed in a randomized trial, and does not hold past five years.

This is the honest part. Read it slowly.

Where the number comes from

A relative riskof 1.00 means “no different from women who never took hormones.” A relative risk of 1.69 means the rate was 69% higher than in never-users. These are relative, not absolute.

An observational study watches what people already chose to do. A randomized trial assigns people at random. Randomized trials are stronger, because women who chose progesterone in France were different from women who chose progestins in ways researchers can only measure imperfectly.

In the E3N cohort of 80,377 postmenopausal French women, followed 8.1 years on average, with 2,354 invasive breast cancers:

• Estrogen + progesterone: RR 1.00 (95% CI 0.83–1.22)
• Estrogen + dydrogesterone: RR 1.16 (0.94–1.43)
• Estrogen + other progestogens: RR 1.69 (1.50–1.91)

That’s the number on the podcasts. It’s accurate. It’s also from an observational study.

What happens at year six

The same researchers followed the same women longer, and split the results by duration. Here’s what they found, as summarized in the British Menopause Society’s consensus statement:

Progesterone still looks better. It just stops looking neutral.

An international expert panel landed exactly there: estrogen combined with oral or vaginal micronized progesterone does not increase breast cancer risk for up to five years of use; there is limited evidence that oral micronized progesterone used beyond five years is associated with increased breast cancer risk; and counseling should cover breast cancer risk regardless of which progestogen is chosen.

What the progesterone label itself says

Here is the sentence, from the February 2026 Prometrium label— a progesterone product — describing a meta-analysis of 24 prospective studies that found a relative risk of 2.08 for estrogen plus progestin:

These studies have not generally found the risk of breast cancer to be different among the various estrogen plus progestin combinations, doses, or routes of administration.

Read that again. The company selling FDA-approved bioidentical progesterone is not claiming a breast cancer advantage on its own label. It has every commercial incentive to. It doesn’t. The identical sentence appears in Bijuva’s 2026 label too. That should tell you how unsettled this is.

One more thing, so the relative numbers mean something

The 2019 Lancet meta-analysis estimated that five years of hormone therapy starting at age 50 would increase breast cancer incidence between ages 50 and 69 by roughly one case per 50 users of estrogen plus daily progestogen.

That’s the size of the thing you’re weighing. Not zero. Not catastrophic. A number a reasonable adult can hold and decide about.

So why isn’t any of this a reason to walk away from progesterone?

Because “not proven in a randomized trial” is not the same as “disproven” — and the trial that would settle it has never been funded by anyone.

What the honest reading gives you isn’t a worse answer. It’s a better question. Not “which molecule is safe?” but “how long am I planning to take this, and what am I optimizing for?”

Progesterone’s edge is real, and it’s strongest exactly where most women actually are: the first five years. If you’re 51, symptomatic, and starting therapy, the observational data is on progesterone’s side — and so is the sleep benefit, which is the one place progesterone has randomized evidence progestins don’t. If you’re 62 and planning another decade, the calculus genuinely shifts, and it shifts toward a conversation about monitoring, not a different pill.

The real decision hiding underneath this search isn’t progesterone or progestin. It’s: am I with someone who can prescribe either one, and who will tell me the truth about both?

Find My HRT Path maps your uterus status, symptoms, medication route, risk history, insurance, and state to the providers that actually fit. It takes about a minute and costs nothing. (Uses sensitive health information — see our privacy policy.)

Which one is actually in my prescription?

Look at the ingredient name, not the marketing. “Progesterone” on a label means micronized progesterone. “Medroxyprogesterone acetate,” “norethindrone acetate,” “levonorgestrel,” or “drospirenone” means a progestin.Some products combine estrogen and a progestogen in one pill or patch. One FDA-approved product — Duavee — contains neither.

The HRT Index Progestogen Verification Matrix

Every row below was read against the product’s FDA label or DailyMed entry. Last checked July 2026.

What this table proves — and it stops an argument cold

Look at the last column for Prometrium and Provera. Both are FDA-approved only for use alongside conjugated estrogens— Premarin — at cyclic dosing.

Now look at what a great many American women are actually taking: an estradiol patch, plus a separate progesterone capsule, 100 mg nightly, continuously.

That combination is off-label on both counts. Different dose. Different estrogen partner. And here’s the part that matters: it’s off-label for the progestin too.Swapping Prometrium for Provera and keeping the estradiol patch fixes nothing, because Provera’s label names conjugated estrogens as well.

“Off-label” is not an argument for one molecule over the other.Any page using “off-label” as a weapon in the progesterone-versus-progestin fight is arguing in bad faith.

FDA-approved estradiol-plus-progestogen combinations do exist: Bijuva (progesterone), Activella and CombiPatch (norethindrone), Climara Pro (levonorgestrel), and Angeliq (drospirenone). That’s a real, specific thing to ask about — and almost nobody thinks to.

What dose of progesterone actually protects the uterus?

The FDA-approved regimen is 200 mg at bedtime for 12 days of each 28-day cycle, alongside conjugated estrogens. The regimen many American women are given — 100 mg nightly, continuously, with an estradiol patch — is off-label on both the dose and the estrogen partner. It is still guideline-supported, and it is the exact dose inside FDA-approved Bijuva. Expert bodies genuinely disagree about it.

Four credible sources. Three different answers about the same capsule.

A 2023 systematic review that examined 84 studies of progestogens and the endometrium put it bluntly: FDA endometrial safety criteria were fulfilled for only someprogestogen formulations, and study quality varied — which should be taken into account when choosing a regimen, especially if off-label use is chosen.

That is the actual state of the evidence in 2026. Not a conspiracy. Not settled, either. If your regimen doesn’t match either FDA label — and many don’t — that’s not an error. But it is worth a real conversation with someone who prescribes both classes and can explain the choice.

Why did my doctor prescribe a progestin instead?

Usually because the evidence for progestins is older, larger, randomized, and — on the outcome that justifies taking a progestogen in the first place — better. The Women’s Health Initiative is the only randomized trial that ever showed a progestogen reducing endometrial cancer risk. It used one specific progestin: medroxyprogesterone acetate.

If you came here believing your doctor handed you the inferior drug, this section is the one that will change your mind.

The randomized evidence progesterone doesn’t have

The Women’s Health Initiative randomized 16,608 postmenopausal women to conjugated estrogens plus medroxyprogesterone acetate, or to placebo.

At 5.6 years — the number printed on the drug labels — endometrial cancer showed a relative risk of 0.83(95% CI 0.49–1.40). Fewer cancers, but not statistically significant.

Then researchers followed those women for 13 years:

• 66 endometrial cancers in the hormone group vs 95 in placebo
• Yearly incidence: 0.06% vs 0.10%
• Hazard ratio 0.65 (95% CI 0.48–0.89), p = 0.007

Fewer cancers. Not “no more cancers.” Fewer. There is no equivalent trial for progesterone. Not a smaller one. Not a weaker one. None.

The finding almost nobody publishes

The same E3N cohort that gave progesterone its breast cancer reputation also asked whether it protects the endometrium. Same researchers. Same women. Different question. Published in the American Journal of Epidemiology in 2014, following 65,630 women for a mean of 10.8 years, with 301 endometrial cancers:

The authors’ own conclusion: micronized progesterone and, to a lesser extent, dydrogesterone, at the doses used in France, may not be sufficient to prevent estrogen-induced endometrial cancers.

How to read that without panicking

Four things have to be said in the same breath. Most pages that mention this study say only one of them:

1. It’s observational. Women who chose progesterone in France differed from women who didn’t.
2. The paper says “at the doses used in France.” French practice commonly used sequential regimens, often shorter than the FDA-approved 12-day, 200 mg schedule.
3. Randomized data show progesterone does control hyperplasia. 6% versus 64% over three years in the Prometrium trial. 0.33% at twelve months in the Bijuva trial.
4. This is a signal that deserves a conversation about duration and monitoring — not a reason to stop progesterone.

But it is also the reason your doctor may not believe she gave you the inferior drug. And she may be right.

The whole picture, in one table

What quality of evidence exists, for which molecule, on which outcome:

Which one will make me feel worse?

Different, not worse. Micronized progesterone is sedating — it’s dosed at bedtime for exactly that reason, and a minority of women get significant dizziness. Progestins can produce mood changes, bloating, and irritability. Neither profile is universal. Not tolerating one is a legitimate reason to try the other.

What the Prometrium label actually reports

From an 875-patient, three-year, placebo-controlled trial of progesterone 200 mg cyclic plus conjugated estrogens:

Look at that last row. Hot flashes fell from 35% to 11% — but that treatment arm included estrogen. The estrogen is what makes you feel better. The progesterone is what makes the estrogen safe to take. Confusing those two is how women end up disappointed by a capsule that was never meant to be the star.

The sedation thing, explained

Your liver converts part of an oral progesterone dose into allopregnanolone, a natural metabolite that acts on the same brain receptors as sleep medication. The Prometrium label instructs bedtime dosing and describes, in a minority of women during initial therapy, extreme dizziness or drowsiness, blurred vision, slurred speech, and difficulty walking.

If that’s been your experience: it’s a known, documented effect of the drug. It is not you failing at hormones. It often improves. It’s also a completely reasonable thing to bring back to your prescriber.

The one place progesterone clearly wins

Micronized progesterone at 300 mg nightly significantly decreases hot flashes and night sweats compared with placebo, and improves sleep. The Menopause Society rates this Level I— the strongest evidence grade they assign. Two caveats: that’s 300 mg, higher than the endometrial-protection dose; and treating hot flashes is not an FDA-approved use of Prometrium. It’s a real finding, used off-label.

What if I’m bleeding or spotting?

If you’re on cyclic progesterone or a progestin — the kind taken 12 to 14 days a month — a monthly withdrawal bleed is expected. That’s the regimen working.

If you’re on a continuous regimen, breakthrough bleeding is common in the first three to six months and usually settles. Bijuva’s trial data: at twelve months, 67.6%of women on the 0.5 mg/100 mg dose and 56.1%on the 1 mg/100 mg dose had complete absence of bleeding, compared with 78.9% on placebo.

The British Menopause Society notes that for most women with unscheduled bleeding on hormone therapy, adjusting the progestogen often controls it. But “often” is not “always,” and only someone who can see your uterus knows which one you are. Make the call. Don’t fill out a form.

Does progesterone cream count?

What the studies found

In one study of progesterone cream used with transdermal estrogen, biopsies showed the cream had provided insufficient endometrial protection in 32% of participants— 27% had endometrial proliferation, and 5% had complex hyperplasia.

The longest study, at 48 weeks, found a cream containing 40 mg of progesterone could not effectively oppose estradiol’s effect on the lining. Five separate studies that measured blood levels after topical progesterone found levels below 5 ng/mL— the minimum believed necessary to convert the endometrium.

The 2016 expert panel’s conclusion came in three parts. Oral micronized progesterone protects the endometrium at 200 mg, 12–14 days a month, for up to five years. Vaginal micronized progesterone may protect at certain doses, off-label. Transdermal micronized progesterone does not provide endometrial protection.

About the wild yam creams

Some over-the-counter creams contain only diosgenin, a compound from wild yam. Manufacturers describe it as a progesterone precursor. Your body cannot convert diosgenin into progesterone. That conversion happens in a laboratory, not in your skin.

Where compounded progesterone stands

The British Menopause Society states there are concerns about the purity, potency, and safety of compounded products, and a lack of evidence that the doses used in compounded preparations provide sufficient endometrial protection. It does not recommend them.

The FDAstates it does not have evidence that compounded “bioidentical hormones” are safe and effective, or safer or more effective than FDA-approved hormone therapy. ACOG recommends FDA-approved options over compounded bioidentical menopausal hormone therapy when an FDA-approved formulation exists.

Compounding does have a narrow, recognized purpose — a dose not available commercially, or an inactive ingredient you can’t tolerate. But FDA-approved and compounded are two different regulatory categories. One has been tested as a finished product. The other has not.

If you are using systemic estrogen with a progesterone cream, this is your next step — not an upgrade. A correction.

Find My HRT Path will tell you honestly if an in-person exam and endometrial evaluation is the right first step. Privacy policy.

Also see: What research says about progesterone cream for menopause →

Can I use an IUD instead of a pill?

Often yes — off-label. The 52 mg levonorgestrel IUD delivers a progestin straight to the uterine lining, with far lower hormone levels in the rest of your body. That’s why it’s the standard fallback for women who can’t tolerate oral progestogens. In the US it is not FDA-approved for endometrial protection during estrogen therapy, though it’s widely used for it and supported by evidence for up to five years.

Levonorgestrel is FDA-approved for uterine protection during estrogen therapy — as a patch. That’s Climara Pro, a weekly estradiol-plus-levonorgestrel patch. The same molecule, in an IUD, is not FDA-approved for that use in the US. Mirena is approved for contraception up to 8 years, and heavy menstrual bleeding up to 5 years. Endometrial protection alongside estrogen is off-label here. In several other countries, it carries that indication on-label.

When the IUD is the right answer:

• Systemic progestogens make you feel awful — mood, bloating, sedation, breast pain
• You’re perimenopausal and still need contraception
• You want no bleeding

See our full guide: Can Mirena be used as progesterone for HRT? →

Did the FDA change the warnings on my prescription in 2026?

On February 12, 2026, the FDA approved labeling changes to six menopausal hormone therapy products — the first batch. Risk statements about cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warning. Twenty-nine drug companies submitted proposed labeling changes; six products have been approved so far. The endometrial cancer warning on estrogen-alone products for women with a uterus remains.

A boxed warningis the FDA’s strongest safety alert. Removing one doesn’t remove a risk. It reflects the agency’s judgment that the warning misrepresented the risk for the women most likely to take the drug.

The six products, verified against the FDA’s tracking page in July 2026

⚠ Read this before you draw a conclusion.Both progestogen-containing products in the first batch contain progesterone. No progestin-containing product has completed a labeling update yet. This is regulatory sequencing, not a safety ranking. The FDA has not said progesterone is safer than progestins. It has said no such thing. We’re publishing this table because other sites will misuse it — and now you’ll recognize it when they do.

What actually changed

On Prometrium, the boxed warning is gone from the label. On Bijuva, the label’s “Recent Major Changes” list shows the Boxed Warning removed in 02/2026.

Bijuva’s Warnings and Precautions still cover Cardiovascular Disorders and Malignant Neoplasms. The label still reports the WHI’s increased risks of clots, stroke, and heart attack, and still reports a relative risk of 1.24 for invasive breast cancer. Removing a boxed warning is not the same as removing a section.

The contraindications are unchanged: breast cancer or a history of it. Estrogen-dependent tumors. Active or past DVT, PE, stroke, or heart attack. Liver disease. Undiagnosed vaginal bleeding. Known clotting disorders. Peanut allergy, for Prometrium.

And the FDA did not remove the endometrial cancer warning from systemic estrogen-alone products for women who still have a uterus. The one warning that survived is precisely the one that makes this entire page necessary.

Full guide: What changed in the 2026 HRT label updates →

Which one fits your situation?

There’s no universal winner. There are eight or nine practical facts about your body, your plan, and your wallet that decide this — and most of them have nothing to do with the studies above. Find yourself in this table.

What to ask, and what to verify before you pay

Don’t walk in asking for “progesterone” or asking to avoid “progestin.” Walk in with the real question: given my uterus status, my estrogen route, my symptoms, my bleeding history, my risk factors, and how long I expect to be on this — what progestogen plan protects my endometrium and is easiest for me to tolerate?

That sentence took this entire page to earn. It’s also the sentence that makes a clinician sit up. You are allowed to ask it.

The four questions that change the appointment

1. “Is what you’re prescribing me FDA-approved, or compounded — and why that one?”
2. “Given how long I expect to be on hormone therapy, how are we thinking about monitoring my uterine lining?”
3. “I’ve read that micronized progesterone may look better for breast cancer short-term but has weaker long-term endometrial data. How do you weigh that for someone like me?”
4. “If I don’t tolerate this one, what’s next — a different molecule, a different route, or an IUD?”

Write them down. Take a photo of this list. Ask them in that order.

The pre-consult verification checklist

If your clinician only offers one option

That’s a real barrier, and it’s the one telehealth solves best. Midi Health runs live video visits with menopause-trained clinicians. In-network with most PPO plans; self-pay is $250 for an initial visit and $150 for continued care. Its standard program uses FDA-approved hormones.

Frequently asked questions

Is progestin the same as progesterone?

No. Progestogen is the umbrella term for the whole family. Progesterone is the specific molecule your ovaries made. Progestin means any synthetic progestogen — medroxyprogesterone acetate, norethindrone acetate, levonorgestrel, drospirenone. Both types protect the uterine lining; they behave differently elsewhere in the body.

Which is safer for HRT, progesterone or progestin?

They're safer at different things. Micronized progesterone shows a lower breast cancer signal in observational studies for the first five years. One synthetic progestin, medroxyprogesterone acetate, holds the only randomized trial evidence of reduced endometrial cancer risk. No randomized trial has ever compared them head to head for cancer outcomes.

Do I need progesterone with an estrogen patch?

If you have a uterus and the patch delivers systemic estrogen, you need a plan for endometrial protection. That plan may be oral progesterone, a progestin, a combined patch, an IUD, or Duavee. Ask which one and why.

Do I need progesterone with vaginal estrogen?

With recommended low-dose vaginal estrogen for genitourinary symptoms, The Menopause Society states a progestogen is generally not indicated. Any bleeding after menopause still requires evaluation.

Do I need progesterone if I had a hysterectomy?

Generally no, because there is no endometrium to protect. Bijuva's label states that if you don't have a uterus, you don't need a progestogen. Your individual history can change that — ask.

Is micronized progesterone FDA-approved?

Yes. Prometrium and its generics are FDA-approved prescription progesterone capsules. Bijuva is an FDA-approved capsule combining estradiol and progesterone.

Is compounded progesterone FDA-approved?

No. Compounded preparations are not FDA-approved finished drug products. The FDA states it does not have evidence that compounded bioidentical hormones are safe and effective, or safer or more effective than FDA-approved hormone therapy. ACOG recommends FDA-approved options when an FDA-approved formulation exists.

Does progesterone cream protect my uterus?

Do not assume it does. An international expert panel concluded that transdermal micronized progesterone does not provide endometrial protection. If you use systemic estrogen and still have a uterus, ask your clinician how your endometrium is being protected and how that is being verified.

Is drospirenone a progestin used in HRT?

Yes. Drospirenone is a synthetic progestin and a spironolactone analog with antimineralocorticoid activity. It appears in Angeliq, an FDA-approved estradiol-plus-drospirenone tablet for women with a uterus. Because it can raise potassium, Angeliq is contraindicated in kidney failure, liver disease, and adrenal insufficiency, and needs caution alongside NSAIDs, potassium-sparing diuretics, potassium supplements, ACE inhibitors, ARBs, and heparin.

Why does Prometrium contain peanut oil?

Peanut oil is the suspension vehicle that carries the micronized hormone. It is why Prometrium is contraindicated in women with peanut allergy. Bijuva's inactive ingredients do not include peanut oil, though Bijuva does contain gelatin. Generic progesterone capsules vary by manufacturer — ask your pharmacist.

Is Bijuva just Prometrium plus estrogen?

No. Bijuva is a separate FDA-approved fixed-dose capsule with its own trial data, its own dosing, and different inactive ingredients.

Why did my doctor prescribe medroxyprogesterone instead of progesterone?

Possible reasons include: medroxyprogesterone has the strongest randomized evidence for preventing endometrial cancer, it is inexpensive and widely covered, it is available in fixed-dose combination products, it does not cause sedation, and it is not contraindicated in peanut allergy. Ask for the rationale. There usually is one.

Can I take progesterone and a progestin together?

Not unless a clinician specifically directs it. They serve the same purpose and their side effects overlap.

What if progesterone makes me depressed or anxious?

Tell your clinician. The Prometrium label reports depression in 19% of women versus 12% on placebo. It is a documented tolerability issue and often a reason to change route, dose, or molecule.

What if I bleed after starting HRT?

Report it. Postmenopausal or unexplained bleeding should be evaluated, not treated as a preference problem.

Is Duavee a progesterone or a progestin?

Neither. Duavee combines conjugated estrogens with bazedoxifene, which protects the uterine lining without a progestogen. It is an FDA-approved alternative for women with a uterus.

Did the FDA say progesterone is safer in 2026?

No. On February 12, 2026 it approved labeling changes to six products, removing certain risk statements from the boxed warning. That is a labeling action, not a comparative safety ruling between progestogens.

Our editorial conclusion

Labeled as what it is: our reading of the evidence above. Not medical advice. Your clinician’s read of your history should outweigh ours.

If you’re starting hormone therapy within ten years of menopause and expect to use it for under five years, FDA-approved micronized progesterone is a well-supported first choice. The short-term breast data favor it. The sleep benefit is real and randomized.

If you’re planning long-term therapy, or you can’t tolerate sedation, or you’re allergic to peanuts,an FDA-approved progestin — or an FDA-approved combination product — carries the stronger randomized endometrial evidence and is not a downgrade. Your doctor did not make a mistake.

If you’re using a progesterone cream with systemic estrogen, neither of the above applies to you yet. Please make a phone call.

And if the honest answer to “which is safer” is it depends on what you’re optimizing for and how long you’ll be here— then the most valuable thing you can do today isn’t swapping a pill. It’s making sure the person prescribing it can offer you both, will tell you which category it falls into, and will tell you the truth about each.

You already knew something was off, or you wouldn’t have searched this. You were right to ask. Now you have the words.

Sources

FDA and regulatory

• FDA. Prometrium (progesterone, USP) capsules — full prescribing information, revised 02/2026. accessdata.fda.gov
• FDA. Bijuva (estradiol and progesterone) capsules — full prescribing information, revised 02/2026. accessdata.fda.gov
• FDA. Menopausal Hormone Therapies with Updated Prescribing Information, content current 02/12/2026.
• FDA. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products, February 12, 2026.
• FDA. Consumer menopause page; statements on compounded bioidentical hormones.
• Provera, Mirena, and Angeliq prescribing information, current labels.

Clinical literature

• Fournier A, et al. (E3N cohort). Breast cancer risk and combined estrogen-progestogen use. Breast Cancer Res Treat 2008;107(1):103–11.
• Fournier A, et al. (E3N cohort — longer follow-up). Breast cancer risk by duration of hormone therapy. J Clin Oncol 2014.
• Fournier A, et al. (E3N endometrial). Unequal risks of endometrial cancer with different progestogens. Am J Epidemiol 2014;180(5):508–17.
• Chlebowski RT, et al. (WHI 13-year endometrial cancer follow-up). J Natl Cancer Inst 2016.
• Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 2019;394(10204):1159–68.
• Stute P, Neulen J, Wildt L. Impact of micronized progesterone on the endometrium. Climacteric 2016;19(4):316–28.
• Stute P, et al. The impact of micronized progesterone on breast cell proliferation. Climacteric 2018.
• The Menopause Society. 2022 Hormone Therapy Position Statement.
• British Menopause Society. Technical report on progestogens and endometrial protection, May 2026.
• ACOG Clinical Consensus No. 6 on compounded bioidentical menopausal hormone therapy.
• PROBES trial protocol (NCT05586724).

Provider statements (each provider’s own site)

• joinmidi.com/menopause · joinmidi.com/hrt · joinmidi.com/store/progesterone

Last verified: July 2026 · Next scheduled re-verification: October 2026